In other words, ‘16% specificity’ indicates that 263 out of 1663 (16%) subjects without clinically significant prostate cancer were correctly identified as negative using a PSA density cutoff ≥0.08 ng/mL/cc. This evidence concerns the gene KLK3 and prostate cancer.